Recent press reports on Medicare’s decision to evaluate coverage policy for the new cancer therapy Provenge were highly critical of the Centers for Medicare and Medicaid Services (CMS) and its role in examining the evidence behind FDA-approved products
Read More...
Read the complete post at http://healthaffairs.org/blog/2010/11/24/thoughtful-purchasing-at-cms/
Posted
Nov 24 2010, 06:21 AM
by
Health Affairs Blog
Filed under: All Categories, Policy, Insurance, Payment, Health Care Costs, Medicare, Coverage, Pharma, Comparative Effectiveness, Innovation, Technology